Charles River Laboratories - Asset Resilience Ratio
Charles River Laboratories (CRL) has an Asset Resilience Ratio of 2.76% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read CRL total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2024)
This chart shows how Charles River Laboratories's Asset Resilience Ratio has changed over time. See CRL total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Charles River Laboratories's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Charles River Laboratories.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $207.10 Million | 2.76% |
| Short-term Investments | $65.00K | 0.0% |
| Total Liquid Assets | $207.16 Million | 2.76% |
Asset Resilience Insights
- Limited Liquidity: Charles River Laboratories maintains only 2.76% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Charles River Laboratories Industry Peers by Asset Resilience Ratio
Compare Charles River Laboratories's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 6.56% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Imagion Biosystems Ltd
AU:IBX |
Diagnostics & Research | 150.16% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Charles River Laboratories (2002–2024)
The table below shows the annual Asset Resilience Ratio data for Charles River Laboratories.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.59% | $194.67 Million | $7.53 Billion | -0.79pp |
| 2023-12-31 | 3.38% | $276.84 Million | $8.20 Billion | +0.29pp |
| 2022-12-31 | 3.09% | $234.91 Million | $7.60 Billion | -0.36pp |
| 2021-12-31 | 3.45% | $242.28 Million | $7.02 Billion | -0.73pp |
| 2020-12-31 | 4.18% | $229.45 Million | $5.49 Billion | -0.91pp |
| 2019-12-31 | 5.09% | $238.96 Million | $4.69 Billion | +0.00pp |
| 2018-12-31 | 5.09% | $196.33 Million | $3.86 Billion | -1.47pp |
| 2017-12-31 | 6.56% | $192.28 Million | $2.93 Billion | +2.09pp |
| 2016-12-31 | 4.48% | $121.40 Million | $2.71 Billion | +3.48pp |
| 2015-12-31 | 0.99% | $20.52 Million | $2.07 Billion | +0.13pp |
| 2014-12-31 | 0.86% | $16.17 Million | $1.89 Billion | +0.18pp |
| 2013-12-31 | 0.68% | $11.16 Million | $1.64 Billion | +0.25pp |
| 2012-12-31 | 0.43% | $6.78 Million | $1.59 Billion | +0.08pp |
| 2011-12-31 | 0.34% | $5.36 Million | $1.56 Billion | -0.22pp |
| 2010-12-31 | 0.57% | $9.83 Million | $1.73 Billion | -1.99pp |
| 2009-12-31 | 2.56% | $56.44 Million | $2.20 Billion | +2.43pp |
| 2008-12-31 | 0.13% | $2.73 Million | $2.16 Billion | -0.41pp |
| 2007-12-31 | 0.53% | $14.96 Million | $2.81 Billion | +0.24pp |
| 2006-12-31 | 0.29% | $7.45 Million | $2.56 Billion | +0.23pp |
| 2005-12-31 | 0.07% | $1.68 Million | $2.54 Billion | +0.06pp |
| 2004-12-31 | 0.01% | $234.00K | $2.63 Billion | -1.64pp |
| 2003-12-31 | 1.65% | $13.16 Million | $799.55 Million | +0.93pp |
| 2002-12-31 | 0.71% | $5.00 Million | $701.34 Million | -- |
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells roden… Read more